Viridian Therapeutics, Inc.
$16.35
+3.0%Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -4.9).
Valuation inputs: P/E -4.9, earnings yield N/A, momentum +3.0%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -47.4%, ROIC -43.8%).
Profitability stack: net margin -4.8%, ROE -47.4%, ROIC -43.8%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +19.7%, momentum +3.0%, net margin -4.8%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Viridian Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Viridian Therapeutics, Inc. Fair Value Envelope
Viridian Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Viridian Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Viridian Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Viridian Therapeutics, Inc. Street Expectations Map
Wall Street analysts project that VRDN stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 36.86, with estimates ranging from a low of 26.00 to a high of 50.00.
The consensus 1-year price target stands at 36.86, with estimates ranging from a low of 26.00 to a high of 50.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Analyst Conviction
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Viridian Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $31.99M and sold $71K worth of VRDN shares, resulting in $31.92M of net buying activity.
3 Months
1.2M
20.00M
0
0.00
+20.0M
+$20.00M
3-6 Months
0
0.00
2.3K
70.80K
-71K
-$71K
6-9 Months
454.5K
10.00M
0
0.00
+10.0M
+$10.00M
9-12 Months
140.1K
1.99M
0
0.00
+2.0M
+$1.99M
Top Buyers
Fairmount Funds Management Llc
Director, 10 Percent Owner:
$30.17M
Morris Arlene
Director
$304K
Ajer Jeffrey Robert
Director
$304K
Gheuens Sarah
Director
$304K
Moses Jennifer K.
Director
$304K
Top Sellers
Tousignant Jennifer
Officer: Chief Legal Officer
$71K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $31.92M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
No Dividend Yield Data
VRDN has not reported any dividend yield values in the available annual periods.
vrdn Dividend History
Learning Layer
Related Guides
Build conviction on VRDN by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.